- Home
- FBLA vs DRUG Comparison
FBLA vs DRUG Comparison
Compare FBLA & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBLA
- DRUG
- Stock Information
- Founded
- FBLA 1908
- DRUG 2019
- Country
- FBLA United States
- DRUG United States
- Employees
- FBLA N/A
- DRUG N/A
- Industry
- FBLA
- DRUG Pharmaceuticals and Biotechnology
- Sector
- FBLA
- DRUG Health Care
- Exchange
- FBLA NYSE
- DRUG Nasdaq
- Market Cap
- FBLA 226.5M
- DRUG 199.7M
- IPO Year
- FBLA N/A
- DRUG N/A
- Fundamental
- Price
- FBLA $11.99
- DRUG $35.46
- Analyst Decision
- FBLA
- DRUG Strong Buy
- Analyst Count
- FBLA 0
- DRUG 7
- Target Price
- FBLA N/A
- DRUG $83.25
- AVG Volume (30 Days)
- FBLA 226.4K
- DRUG 67.0K
- Earning Date
- FBLA 08-22-2025
- DRUG 08-13-2025
- Dividend Yield
- FBLA N/A
- DRUG N/A
- EPS Growth
- FBLA N/A
- DRUG N/A
- EPS
- FBLA N/A
- DRUG N/A
- Revenue
- FBLA $66,405,000.00
- DRUG N/A
- Revenue This Year
- FBLA N/A
- DRUG N/A
- Revenue Next Year
- FBLA N/A
- DRUG N/A
- P/E Ratio
- FBLA N/A
- DRUG N/A
- Revenue Growth
- FBLA N/A
- DRUG N/A
- 52 Week Low
- FBLA $9.81
- DRUG $0.94
- 52 Week High
- FBLA $12.74
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- FBLA N/A
- DRUG 74.46
- Support Level
- FBLA N/A
- DRUG $25.56
- Resistance Level
- FBLA N/A
- DRUG $26.83
- Average True Range (ATR)
- FBLA 0.00
- DRUG 1.83
- MACD
- FBLA 0.00
- DRUG 1.03
- Stochastic Oscillator
- FBLA 0.00
- DRUG 84.29
About FBLA FB BANCORP INC
FB Bancorp Inc is a holding company. The company operates through its subsidiary Fidelity Bank. Fidelity business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market areas. The services of the company also include residential construction loans, commercial real estate loans (which includes commercial mortgage, commercial construction and land development loans), commercial loans (which includes commercial and industrial, small business and other commercial loans not secured by real estate), home equity loans and lines of credit, and consumer loans.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.